113 related articles for article (PubMed ID: 37944494)
1. Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts.
Pimenoff VN; Gray P; Louvanto K; Eriksson T; Lagheden C; Söderlund-Strand A; Dillner J; Lehtinen M
Cell Host Microbe; 2023 Nov; 31(11):1921-1929.e3. PubMed ID: 37944494
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
4. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Natunen K; Nieminen P; Paavonen J; Palmroth J; Petäjä T; Pukkala E; Vänskä S; Cheuvart B; Soila M; Bi D; Struyf F
Cancer Med; 2021 Nov; 10(21):7759-7771. PubMed ID: 34581025
[TBL] [Abstract][Full Text] [Related]
6. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
8. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
9. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.
Vänskä S; Luostarinen T; Baussano I; Apter D; Eriksson T; Natunen K; Nieminen P; Paavonen J; Pimenoff VN; Pukkala E; Söderlund-Strand A; Dubin G; Garnett G; Dillner J; Lehtinen M
J Infect Dis; 2020 Aug; 222(6):948-956. PubMed ID: 32161969
[TBL] [Abstract][Full Text] [Related]
10. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Osterlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896
[TBL] [Abstract][Full Text] [Related]
11. Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
Baussano I; Lazzarato F; Ronco G; Lehtinen M; Dillner J; Franceschi S
J Infect Dis; 2017 Aug; 216(3):336-344. PubMed ID: 28859431
[TBL] [Abstract][Full Text] [Related]
12. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
Gray P; Palmroth J; Luostarinen T; Apter D; Dubin G; Garnett G; Eriksson T; Natunen K; Merikukka M; Pimenoff V; Söderlund-Strand A; Vänskä S; Paavonen J; Pukkala E; Dillner J; Lehtinen M
Int J Cancer; 2018 Jun; 142(12):2491-2500. PubMed ID: 29377141
[TBL] [Abstract][Full Text] [Related]
14. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
16. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
17. Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women.
Feder MA; Kulasingam SL; Kiviat NB; Mao C; Nelson EJ; Winer RL; Whitham HK; Lin J; Hawes SE
J Womens Health (Larchmt); 2019 Oct; 28(10):1428-1435. PubMed ID: 31264912
[No Abstract] [Full Text] [Related]
18. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.
Malagón T; Laurie C; Franco EL
Expert Rev Vaccines; 2018 May; 17(5):395-409. PubMed ID: 29715059
[TBL] [Abstract][Full Text] [Related]
20. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
